Skip to Main Content

Paper Details

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Breast Cancer Res Treat
28
2017
Author NameAffiliation
Paul HarnettCrown Princess Mary Cancer Centre Westmead
  • 1 - 1

Datasets

Release 1.2